ArticleBMJ open2023

Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.

Kenrick Ng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.